News

US FDA approves KalVista Pharma's swelling disorder drug
KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug for a type of hereditary ...
India Today on MSN1h
Kanwar Yatra route food vendors now need QR licences, says UP government
In Uttar Pradesh, the updated protocol mandates round-the-clock inspections of food stalls and kitchens along the Yatra route ...
FDA and EMA authorise AB Science’s Phase III trial of prostate cancer treatment
The Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have authorised AB Science’s confirmatory ...
KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioe…
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved ...
STAT3h
Inside the staff exodus and tanking morale that threaten Makary’s FDA
WASHINGTON — The steady erosion of experienced staff at the Food and Drug Administration is slowly compromising the agency’s ...
'Gas Station Heroin': The Drug Sold As A Dietary Supplement That's Linked To Overdoses And Deaths
The US Food and Drug Administration (FDA) has issued an urgent warning about tianeptine – a substance marketed as a dietary ...
Edex Live on MSN2h
Maharashtra FDA allows homoeopathy doctors to prescribe allopathic medicines; stirs debate
In a significant development, the Maharashtra Food and Drug Administration (FDA) has directed chemists across the state to ...
KalVista Pharmaceuticals Shares Rise on FDA Approval of Hereditary Angioedema Drug
KalVista Pharmaceuticals shares jumped in premarket trading Monday after the company said it has received regulatory approval for its treatment of hereditary angioedema. Shares traded 20% higher ahead ...
Obesity drug prices are dropping, but getting a steady supply remains a challenge
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...